Search tips
Search criteria 


Logo of neurotherwww.springer.comThis journalToc AlertsSubmit OnlineOpen Choice
Neurotherapeutics. 2008 October; 5(4): 601–606.
Published online 2008 October 1. doi:  10.1016/j.nurt.2008.07.005
PMCID: PMC2628543

Facioscapulohumeral muscular dystrophy


Facioscapulohumeral muscular dystrophy (FSHD), a dominantly inherited disorder, is the third most common dystrophy after Duchenne and myotonic muscular dystrophy. No known effective treatments exist for FSHD. The lack of an understanding of the underlying pathophysiology remains an obstacle in the development of targeted therapeutic interventions. The genetic defect is a loss of a critical number of a repetitive element (D4Z4) in the 4q subtelomeric region. The loss of the repeats results in specific changes in chromatin structure, although neither the molecular nor the cellular consequences of this change are known. Nevertheless, these epigenetic changes in chromatin structure offer a potential therapeutic target. This review discusses current management strategies in FSHD as well as potential therapeutic interventions to slow down or reverse the progressive muscle atrophy and weakness.

Key Words: FSHD, facioscapulohumeral muscular dystrophy, muscular dystrophy, myostatin, chromosome 4


1. Padberg GW. Facioscapulohumeral disease. Leiden, The Netherlands: University of Leiden; 1982.
2. Wohlgemuth M, van der Kooi EL, van Kesteren RG, van der Maarel SM, Padberg GW. Ventilatory support in facioscapulohumeral muscular dystrophy. Neurology. 2004;63:176–178. doi: 10.1212/01.WNL.0000133126.86377.E8. [PubMed] [Cross Ref]
3. Fitzsimons RB, Gurwin EB, Bird AC. Retinal vascular abnormalities in facioscapulohumeral muscular dystrophy: a general association with genetic and therapeutic implications. Brain. 1987;110:631–648. doi: 10.1093/brain/110.3.631. [PubMed] [Cross Ref]
4. Padberg GW, Brouwer OF, de Keizer RF, et al. On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy. Muscle Nerve 1995:S73–S80. [PubMed]
5. Shields CL, Zahler J, Falk N, et al. Neovascular glaucoma from advanced Coats disease as the initial manifestation of facioscapulohumeral dystrophy in a 2-year-old child. Arch Ophthalmol. 2007;125:840–842. doi: 10.1001/archopht.125.6.840. [PubMed] [Cross Ref]
6. Laforêt P, de Toma C, Eymard B, et al. Cardiac involvement in genetically confirmed facioscapulohumeral muscular dystrophy. Neurology. 1998;51:1454–1456. doi: 10.1212/WNL.51.5.1454. [PubMed] [Cross Ref]
7. Wijmenga C, Hewitt JE, Sandkuijl LA, et al. Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy. Nat Genet. 1992;2:26–30. doi: 10.1038/ng0992-26. [PubMed] [Cross Ref]
8. Lunt PW, Jardine PE, Koch MC, et al. Correlation between fragment size at D4F104S1 and age of onset or at wheelchair use, with a possible generational effect, accounts for much phenotypic variation in 4q35-facioscapulohumeral muscular dystrophy (FSHD) [Erratum in: Hum Mol Genet 1995;4:1243–1244] Hum Mol Genet. 1995;4:951–958. doi: 10.1093/hmg/4.5.951. [PubMed] [Cross Ref]
9. Tawil R, Forrester J, Griggs RC, The FSH-DY Group et al. Evidence for anticipation and association of deletion size with severity of facioscapulohumeral muscular dystrophy. Ann Neurol. 1996;39:744–748. doi: 10.1002/ana.410390610. [PubMed] [Cross Ref]
10. Tupler R, Berardinelli A, Barbierato L, et al. Monosomy of distal 4q does not cause facioscapulohumeral muscular dystrophy. J Med Genet. 1996;33:366–370. doi: 10.1136/jmg.33.5.366. [PMC free article] [PubMed] [Cross Ref]
11. Lyle R, Wright TJ, Clark LN, Hewitt JE. The FSHD-associated repeat, D4Z4, is a member of a dispersed family of homeobox-containing repeats, subsets of which are clustered on the short arms of the acrocentric chromosomes. Genomics. 1995;28:389–397. doi: 10.1006/geno.1995.1166. [PubMed] [Cross Ref]
12. Gabriëls J, Beckers MC, Ding H, et al. Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. Gene. 1999;236:25–32. doi: 10.1016/S0378-1119(99)00267-X. [PubMed] [Cross Ref]
13. Hewitt JE, Lyle R, Clark LN, et al. Analysis of the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystrophy. Hum Mol Genet. 1994;3:1287–1295. doi: 10.1093/hmg/3.8.1287. [PubMed] [Cross Ref]
14. Clapp J, Mitchell LM, Bolland DJ, et al. Evolutionary conservation of a coding function for D4Z4, the tandem DNA repeat mutated in facioscapulohumeral muscular dystrophy. Am J Hum Genet. 2007;81:264–279. doi: 10.1086/519311. [PubMed] [Cross Ref]
15. van Deutekom JCT, Lemmers RJLF, Grewal PK, et al. Identification of the first gene (FRG1) from the FSHD region on human chromosome 4q35. Hum Mol Genet. 1996;5:581–590. doi: 10.1093/hmg/5.5.581. [PubMed] [Cross Ref]
16. Grewal PK, Todd LC, van der Maarel S, Frants RR, Hewitt JE. FRG1, a gene in the FSH muscular dystrophy region on human chromosome 4q35, is highly conserved in vertebrates and invertebrates. Gene. 1998;216:13–19. doi: 10.1016/S0378-1119(98)00334-5. [PubMed] [Cross Ref]
17. van Koningsbruggen S, Dirks RW, Mommaas AM, et al. FRG1P is localised in the nucleolus, Cajal bodies, and speckles. J Med Genet. 2004;41:e46–e46. doi: 10.1136/jmg2003.012781. [PMC free article] [PubMed] [Cross Ref]
18. Gabellini D, Green M, Tupler R. Inappropriate gene activation in FSHD: a repressor complex binds a chromosomal repeat deleted in dystrophic muscle. Cell. 2002;110:339–348. doi: 10.1016/S0092-8674(02)00826-7. [PubMed] [Cross Ref]
19. Jiang G, Yang F, van Overveld PG, Vedanarayanan V, van der Maarel S, Ehrlich M. Testing the position-effect variegation hypothesis for facioscapulohumeral muscular dystrophy by analysis of histone modification and gene expression in subtelomeric 4q. Hum Mol Genet. 2003;12:2909–2921. doi: 10.1093/hmg/ddg323. [PubMed] [Cross Ref]
20. Winokur ST, Chen YW, Masny PS, et al. Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation. Hum Mol Genet. 2003;12:2895–2907. doi: 10.1093/hmg/ddg327. [PubMed] [Cross Ref]
21. Osborne RJ, Welle S, Venance SL, Thornton CA, Tawil R. Expression profile of FSHD supports a link between retinal vasculopathy and muscular dystrophy. Neurology. 2007;68:569–577. doi: 10.1212/01.wnl.0000251269.31442.d9. [PubMed] [Cross Ref]
22. Masny PS, Bengtsson U, Chung SA, et al. Localization of 4q35.2 to the nuclear periphery: is FSHD a nuclear envelope disease? Hum Mol Genet. 2004;13:1857–1871. doi: 10.1093/hmg/ddh205. [PubMed] [Cross Ref]
23. de Greef JC, Wohlgemuth M, Chan OA, et al. Hypomethylation is restricted to the D4Z4 repeat array in phenotypic FSHD. Neurology. 2007;69:1018–1026. doi: 10.1212/01.wnl.0000271391.44352.fe. [PubMed] [Cross Ref]
24. Petrov A, Allinne J, Pirozhkova I, Laoudj D, Lipinski M, Vassetzky YS. A nuclear matrix attachment site in the 4q35 locus has an enhancer-blocking activity in vivo: implications for the facioscapulo-humeral dystrophy. Genome Res. 2008;18:39–45. doi: 10.1101/gr.6620908. [PubMed] [Cross Ref]
25. Orrell RW, Tawil R, Forrester J, Kissel JT, Mendell JR, Figlewicz DA. Definitive molecular diagnosis of facioscapulohumeral dystrophy. Neurology. 1999;52:1822–1826. doi: 10.1212/WNL.52.9.1822. [PubMed] [Cross Ref]
26. van Deutekom JC, Bakker E, Lemmers RJ, et al. Evidence for subtelomeric exchange of 3.3 kb tandemly repeated units between chromosomes 4q35 and 10q26: implications for genetic counselling and etiology of FSHD1. Hum Mol Genet. 1996;5:1997–2003. doi: 10.1093/hmg/5.12.1997. [PubMed] [Cross Ref]
27. Bushby KM, Pollitt C, Johnson MA, Rogers MT, Chinnery PF. Muscle pain as a prominent feature of facioscapulohumeral muscular dystrophy (FSHD): four illustrative case reports. Neuromuscul Disord. 1998;8:574–579. doi: 10.1016/S0960-8966(98)00088-1. [PubMed] [Cross Ref]
28. Fitzsimons RB. Retinal vascular abnormalities in FSHD: a therapeutic message; clues to pathogenesis. In: Upadhyaya M, Cooper DN, editors. Facioscapulohumeral muscular dystrophy (FSHD): clinical medicine and molecular cell biology. New York: BIOS Scientific Publishers; 2004. pp. 185–195.
29. McCartney N, Moroz D, Gamer SH, McComas AJ. The effects of strength training in patients with selected neuromuscular disorders. Med Sci Sports Exerc. 1988;20:362–368. doi: 10.1249/00005768-198808000-00006. [PubMed] [Cross Ref]
30. Milner-Brown HS, Miller RG. Muscle strengthening through high-resistance weight training in patients with neuromuscular disorders. Arch Phys Med Rehabil. 1988;69:14–19. [PubMed]
31. Vignos PJ, Watkins MP. The effect of exercise in muscular dystrophy. JAMA. 1966;197:843–848. doi: 10.1001/jama.1966.03110110067015. [PubMed] [Cross Ref]
32. Olsen DB, Ørngreen MC, Vissing J. Aerobic training improves exercise performance in facioscapulohumeral muscular dystrophy. Neurology. 2005;64:1064–1066. doi: 10.1212/01.WNL.0000150584.45055.27. [PubMed] [Cross Ref]
33. van der Kooi EL, Vogels OJ, van Asseldonk RJ, et al. Strength training and albuterol in facioscapulohumeral muscular dystrophy. Neurology. 2004;63:702–708. doi: 10.1212/01.WNL.0000134660.30793.1F. [PubMed] [Cross Ref]
34. Bunch WH, Siegel IM. Scapulothoracic arthrodesis in facioscapulohumeral muscular dystrophy: review of seventeen procedures with three to twenty-one-year follow up. J Bone Joint Surg Am. 1993;75:372–376. [PubMed]
35. Copeland SA, Levy O, Warner GC, Dodenhoff RM. The shoulder in patients with muscular dystrophy. Clin Orthop. 1999;368:80–91. [PubMed]
36. Giannini S, Faldini C, Pagkrati S, et al. Fixation of winged scapula in facioscapulohumeral muscular dystrophy. Clin Med Res. 2007;5:155–162. doi: 10.3121/cmr.2007.736. [PubMed] [Cross Ref]
37. Rhee YG, Ha JH. Long-term results of scapulothoracic arthrodesis of facioscapulohumeral muscular dystrophy. J Shoulder Elbow Surg. 2006;15:445–450. doi: 10.1016/j.jse.2005.10.015. [PubMed] [Cross Ref]
38. Mummery CJ, Copeland SA, Rose MR. Scapular fixation in muscular dystrophy. Cochrane Database Syst Rev 2003;(3): CD003278. [PubMed]
39. Wolfe GI, Young PK, Nations SP, Bulkhead WZ, McVey AL, Barohn RJ. Brachial plexopathy following thoracoscapular fusion in facioscapulohumeral muscular dystrophy. Neurology. 2005;64:572–573. doi: 10.1212/01.WNL.0000150907.82191.05. [PubMed] [Cross Ref]
40. Mackenzie WG, Riddle EC, Earley JL, Sawatzky BJ. A neurovascular complication after scapulothoracic arthrodesis. Clin Orthop Relat Res 2003 Mar;(408):157–161. [PubMed]
41. Sansone V, Boynton J, Palenski C. Use of gold weights to correct lagophthalmos in neuromuscular disease. Neurology. 1997;48:1500–1503. doi: 10.1212/WNL.48.6.1500. [PubMed] [Cross Ref]
42. Munsat TL, Piper D, Cancilla P, Mednick J. Inflammatory myopathy with facioscapulohumeral distribution. Neurology. 1972;22:335–347. doi: 10.1212/WNL.22.4.335. [PubMed] [Cross Ref]
43. Bates D, Stevens JC, Hudgson P. “Polymyositis” with involvement of facial and distal musculature: one form of the facioscapulohumeral syndrome? J Neurol Sci. 1973;19:105–108. doi: 10.1016/0022-510X(73)90061-0. [PubMed] [Cross Ref]
44. Wulff JD, Lin JT, Kepes JJ. Inflammatory facioscapulohumeral muscular dystrophy and Coats syndrome. Ann Neurol. 1982;12:398–401. doi: 10.1002/ana.410120415. [PubMed] [Cross Ref]
45. Tawil R, McDermott MP, Pandya S, The FSH-DY Group et al. A pilot study of prednisone in facioscapulohumeral muscular dystrophy. Neurology. 1997;48:46–49. doi: 10.1212/WNL.48.1.46. [PubMed] [Cross Ref]
46. Benson DW, Foley-Nelson T, Chance WT, Zhang FS, James JH, Fischer JE. Decreased myofibrillar protein breakdown following treatment with clenbuterol. J Surg Res. 1991;50:1–5. doi: 10.1016/0022-4804(91)90002-4. [PubMed] [Cross Ref]
47. Matlin CA, Hay SM, McMillan DN, Delday MI. Tissue specific responses to clenbuterol; temporal changes in protein metabolism of striated muscle and visceral tissues from rats. Growth Regul. 1992;2:161–166. [PubMed]
48. Agbenyega ET, Wareham AC. Effect of clenbuterol on skeletal muscle atrophy in mice induced by the glucocorticoid dexamethasone. Comp Biochem Physiol Comp Physiol. 1992;102:141–145. doi: 10.1016/0300-9629(92)90026-M. [PubMed] [Cross Ref]
49. Choo JJ, Horan MA, Little RA, Rothwell NJ. Muscle wasting associated with endotoxemia in the rat: modification by the β2-adrenoceptor agonist clenbuterol. Biosci Rep. 1989;9:615–621. doi: 10.1007/BF01119805. [PubMed] [Cross Ref]
50. Hayes A, Williams DA. Examining the potential drug therapies for muscular dystrophy utilising the dy/dy mouse: I. Clenbuterol. J Neurol Sci. 1998;157:122–128. doi: 10.1016/S0022-510X(98)00084-7. [PubMed] [Cross Ref]
51. Zeman RJ, Ludemann R, Etlinger JD. Clenbuterol, a β2 agonist, retards atrophy in denervated muscles. Am J Physiol. 1987;252:E152–E155. [PubMed]
52. Martineau L, Horan MA, Rothwell NJ, Little RA. Salbutamol, a β2-adrenoceptor agonist, increases skeletal muscle strength in young men [Erratum in: Clin Sci 1993;84(6):following XX] Clin Sci (Lond) 1992;83:615–621. [PubMed]
53. Kissel JT, McDermott MP, Mendell JR, The FSH-DY Group et al. Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral muscular dystrophy. Neurology. 2001;57:1434–1440. doi: 10.1212/WNL.57.8.1434. [PubMed] [Cross Ref]
54. Kemp GJ, Taylor DJ, Dunn JF, Frostick SP, Radda GK. Cellular energetics of dystrophic muscle. J Neurol Sci. 1993;116:201–206. doi: 10.1016/0022-510X(93)90326-T. [PubMed] [Cross Ref]
55. Pulido SM, Passaquin AC, Leijendekker WJ, Challet C, Walliman T, Ruegg UT. Creatine supplementation improves intracellular Ca2+ handling and survival in mdx skeletal muscle cells. GEBS Lett. 1998;439:357–362. [PubMed]
56. Walter MC, Lochmüller H, Reilich P, et al. Creatine monohydrate in muscular dystrophies: a double-blind placebo controlled clinical study. Neurology. 2000;54:1848–1850. doi: 10.1212/WNL.54.9.1848. [PubMed] [Cross Ref]
57. Rose MR, Tawil R. Drug treatment for facioscapulohumeral muscular dystrophy. Cochrane Database Syst Rev 2004;(2): CD002276. [PubMed]
58. Patel K, Amthor H. The function of myostatin and strategies of myostatin blockade: new hope for therapies aimed at promoting growth of skeletal muscle. Neuromuscul Disord. 2005;15:117–126. doi: 10.1016/j.nmd.2004.10.018. [PubMed] [Cross Ref]
59. Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008;63:561–571. doi: 10.1002/ana.21338. [PubMed] [Cross Ref]
60. van Overveld PG, Enthoven L, Ricci E, et al. Variable hypomethylation of D4Z4 in facioscapulohumeral muscular dystrophy. Ann Neurol. 2005;58:569–576. doi: 10.1002/ana.20625. [PubMed] [Cross Ref]
61. van der Kooi EL, de Greef JC, Wohlgemuth M, et al. No effect of folic acid and methionine supplementation on D4Z4 methylation in patients with facioscapulohumeral muscular dystrophy. Neuromuscul Disord. 2006;16:766–769. doi: 10.1016/j.nmd.2006.08.005. [PubMed] [Cross Ref]
62. Lee SJ, Reed LA, Davies MV, et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci U S A. 2005;102:18117–18122. doi: 10.1073/pnas.0505996102. [PubMed] [Cross Ref]
63. Lachey J, Pullen A, Pearsall R, Seehra J. Novel myostatin inhibitors increase muscle mass in wild-type and mdx mice. Neuromuscul Disord. 2007;17:785–785.
64. Vilquin JT, Marolleau JP, Sacconi S, et al. Normal growth and regenerating ability of myoblasts from unaffected muscles of facioscapulohumeral muscular dystrophy patients. Gene Ther. 2005;12:1651–1662. doi: 10.1038/ [PubMed] [Cross Ref]
65. Morosetti R, Mirabella M, Gliubizzi C, et al. Isolation and characterization of mesoangioblasts from facioscapulohumeral muscular dystrophy muscle biopsies. Stem Cells. 2007;25:3173–3182. doi: 10.1634/stemcells.2007-0465. [PubMed] [Cross Ref]

Articles from Neurotherapeutics are provided here courtesy of Springer